Ultime notizie per InMode (NASDAQ:INMD) Azioni

InMode

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

InMode Ltd

Needham analyst Mike Matson reiterates InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Hold.

News

Reiteration

Analyst Ratings

INMD

Needham Reiterates Hold on InMode

Guidance

InMode Cuts FY24 Revenue Outlook From $430M - $440M To $410M - $420M (Est $419.925M), Adj EPS Guidance Remains The Same As In Previous Guidance At $1.92 - $1.96 (Est $1.87)

InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.63 by 11.11 percent. This is a 14.75 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $130.23 million which beat the analyst consensus estimate of $127.00 million by 2.54 percent. This is a 5.78 percent increase over sales of $123.11 million the same period last year.

Earnings

Earnings Beats

InMode Q3 2024 Adj EPS $0.70 Beats $0.63 Estimate, Sales $130.23M Beat $127.00M Estimate

Legal

InMode Says It Is Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales Of Morpheus8 Radiofrequency Devices and Cartridge Accessories

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital analyst Anthony Chukumba initiated coverage on Grocery Outlet Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) with a Hold rating and announced a price target of $17. Grocery Outlet shares closed at $16.45 on Wednesday. <a href="https://www.benzinga.com/quote/GO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Aaron Gal initiated coverage on Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with an Outperform rating and announced a price target of $105. Gilead Sciences shares closed at $85.82 on Wednesday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Jim Salera initiated coverage on First Watch Restaurant Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Overweight rating and announces Price Target of $20. First Watch Restaurant shares closed at $14.77 on Wednesday. <a href="https://www.benzinga.com/quote/FWRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Sam Eiber initiated coverage on InMode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Buy rating and announced a price target of $25. InMode shares closed at $16.65 on Wednesday. <a href="https://www.benzinga.com/quote/INMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy rating and announced a price target of $30. Alumis shares closed at $11.20 on Wednesday. <a href="https://www.benzinga.com/quote/ALMS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GILD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-1024x522.png" alt="" class="wp-image-600656" style="width:638px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149.png 1317w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Price Target

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ALMS

FWRG

GILD

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BTIG analyst Sam Eiber initiates coverage on InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Buy rating and announces Price Target of $25.

BTIG Initiates Coverage On InMode with Buy Rating, Announces Price Target of $25

Barclays analyst Matt Miksic maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Overweight and lowers the price target from $29 to $27.

Barclays Maintains Overweight on InMode, Lowers Price Target to $27

As previously discussed at the beginning of this year, InMode introduced two new platforms to the market, resulting in a transition phase with pre-orders received during the first half of this year. Management is happy to report that, by the end of the third quarter, InMode was able to fulfil all pre-orders and become current with all deliveries of incoming orders. This resulted in recognition during the third quarter of approximately $31.9 million of revenues that were previously deferred. Additionally, management continues to see macro-economic factors impacting the aesthetics industry. Management preliminarily expects the following financial results for the third quarter of 2024:
<ul>
<li>Revenue to be in the range of&nbsp;$130.0 million&nbsp;to&nbsp;$130.1 million (including $31.9 million in revenue from new platform pre-orders received in the first half of this year that were delivered and recognized as revenue in the third quarter of 2024)</li>
<li>Non-GAAP1 gross margin to be in the range of 81% to 82%</li>
<li>Full year 2024 revenue to be $410 million to $420 million as compared to prior guidance of $430 million to $440 million</li>
</ul>

InMode Expects Q3 Revenue Between $130M-$130.1M (Including $31.9M In Revenue From First Half Of 2024 Pre-Orders), Decreases Full Year 2024 Guidance To $410M-$420M

WIIM

InMode shares are trading higher after the company announced it approved a share repurchase program.

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Shares of Calavo Growers, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) rose sharply during Tuesday's session as the company posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/24/09/40782532/calavo-growers-stock-climbs-after-q3-results-dividend-increase-details">results for its third quarter.</a>
Calavo Growers reported quarterly earnings of 57 cents per share, which beat the analyst consensus estimate of 43 cents by 32.56%.&nbsp; The company reported quarterly sales of $179.6 million which beat the analyst consensus estimate of $178.54 million.
The company increased its cash dividend by 10 cents per share to 20 cents per share to be paid on Oct. 30, 2024, to shareholders of record on Oct. 2, 2024
Calavo Growers shares jumped 12.5% to $26.76 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Mission Produce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) shares jumped 17.1% to $12.52 after the company reported better-than-expected third-quarter financial results.</li>
<li>Avid Bioservices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) shares jumped 15.8% to $10.37 following a narrower-than-expected quarterly loss.</li>
<li>Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) rose 12.5% to $157.33 following upbeat quarterly earnings.</li>
<li>Centessa Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) gained 12.3% to $16.77 after the company announced interim data from an ongoing Phase 1 trial of ORX750 in acutely sleep-deprived healthy volunteers.</li>
<li>Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) rose 12.1% to $156.48 after BTIG raised its price target on the stock from $150 to $165.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) gained 11.8% to $10.14. Terns announced a $125 million proposed public offering.</li>
<li>Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) jumped 10.8% to $15.72 after the company reported topline data from the THRIVE phase 3 clinical trial of VRDN-001 in patients with active thyroid eye disease.</li>
<li>InMode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) gained 10.7% to $17.19 after announcing a share repurchase program of up to 7.68 million shares.</li>
<li>Kornit Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) rose 8.8% to $19.83. Kornit Digital's board authorized a $100 million share repurchase program.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) jumped 8.4% to $1.55.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) rose 5.5% to $19.92.</li>
<li>Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) gained 5.3% to $384.32.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 4% to $224.82, buoyed by positive tidings from China. Vehicle insurance registration data for Tesla vehicles came in at a robust 16,200 for the week ended Sept. 8, CnEVPost reported, citing data provided by Li Auto. This compares to the previous week's number of 14,400 units and marked the strongest increase since the 17,500 units reported for the third week of June..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40790502/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>

Intraday Update

Movers

BOOT

CDMO

CNTA

CVGW

KRNT

ORCL

TERN

TSLA

VRDN

WING

Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday

The Company&#39;s ordinary share repurchases, if any, will be funded with available cash. Share repurchases may be commenced, suspended or discontinued at any time.

Buybacks

InMode Board Approves Share Repurchase Program Of Up To 7.68M Ordinary Shares

Biotech

General

CORRECTTION: InMed Ticker Is 'INM'

InMode shares are trading lower after the company reported worse-than-expected Q2 revenue results.

InMode Q2 2024 Adj. EPS $0.46 Beats $0.38 Estimate, Sales $102.622M Miss $104.762M Estimate

Jefferies analyst Matthew Taylor downgrades InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) from Buy to Hold and lowers the price target from $21 to $19.

Downgrades

Jefferies Downgrades InMode to Hold, Lowers Price Target to $19

InMode Announces Morpheus8 FDA 510(k) Clearance For Soft Tissue Contraction For Fractional Radiofrequency Microneedling

Barclays analyst Matt Miksic maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Overweight and lowers the price target from $33 to $29.

Barclays Maintains Overweight on InMode, Lowers Price Target to $29

Canaccord Genuity analyst Caitlin Cronin maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Hold and lowers the price target from $21 to $16.

Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16

InMode granted injunction against online sellers for Morpheus8 devices

InMode Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

InMode Non-GAAP EPS of $0.70 beats by $0.09, revenue of $130.23M beats by $3.32M

Reports Q3 revenue $130.2M, consensus $127M. "The Q3 presented ongoing challenges for InMode (INMD)," said Moshe Mizrahy, CEO. "Macroeconomic condi...

InMode reports Q3 non-GAAP EPS 70c, consensus 63c

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript

In a report released today, Michael Matson from Needham maintained a Hold rating on InMode (INMD – Research Report). The company's shares opened to...

InMode (INMD) Gets a Hold from Needham

Inmode ( ($INMD) ) has realeased its Q3 earnings. Here is a breakdown of the information Inmode presented to its investors. InMode Ltd., a prominen...

InMode's Q3 2024: Revenue Growth Amid Challenges

InMode: A Deep Dive After Q3 Earnings

InMode: $25/Share Is Closer Than You Think

AIRS

APYX

ARVN

AXTA

BASFY

BIIB

BLKB

BPMC

COCO

CRMD

CRTO

CUTR

CVEO

CWEN

EADSF

ENIC

EXTR

FLEX

FVRR

GEHC

GRMN

HESM

ITCI

IVPAF

LKNCY

NAVI

NBIX

NVCR

OMCL

OPCH

OTIS

PUMP

ROCK

RVNC

Press Releases

InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform

InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

InMode to Present at Upcoming Investor Conferences

InMode to Present at 2024 Baird Global Healthcare Conference

InMode Announces Share Repurchase Program of Up to 7.68 Million Shares

InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

Comments

InMode

Notizie

Ultime notizie per InMode (NASDAQ:INMD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO